Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Ascletis In-Licenses Alnylam’s RNAi Drug for Liver Cancer

publication date: Jul 12, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Ascletis Pharmaceuticals, a US-China JV that made headlines one year ago when it announced $100 million in initial startup capital, has in-licensed China rights to its first drug candidate, an innovative RNAi molecule from Alnylam Pharma. ALN-VSP is being developed for liver cancers including hepatocellular carcinoma (HCC). Ascletis will have exclusive rights for ALN-VSP in China, Hong Kong, Macau and Taiwan. Alnylam will retain rights to the drug for the rest of the world. More details...

Stock Symbol: (NSDQ: ALNY)

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners